Literature DB >> 22705204

The presence of Tregs does not preclude immunity to reinfection with Leishmania braziliensis.

Sarah C Falcão1, Tatiana R de Moura, Jorge Clarêncio, Cláudia Brodskyn, Aldina Barral, Camila I de Oliveira.   

Abstract

Leishmania spp. cause a broad spectrum of diseases collectively known as leishmaniasis. Leishmania braziliensis is the main etiological agent of American cutaneous leishmaniasis and mucocutaneous leishmaniasis. During experimental infection with L. braziliensis, BALB/c mice develop an adaptive immune response that is associated with lesion healing and, in parallel, parasite persistence within draining lymph nodes (dLNs). In the Leishmania major model of cutaneous leishmaniasis, regulatory T cells (Tregs) play an important role in immune regulation, preventing pathological immune responses but at the same time precluding sterile cure. In this study we investigated the role of Tregs during experimental infection with L. braziliensis. CD4(+)CD25(+) T cells were detected throughout the duration of clinical disease both at the ear and in dLNs of infected mice. These cells expressed Treg markers such as glucocorticoid-induced TNF-receptor-related protein (GITR), the α chain of the αεβ7 integrin (CD103), and the forkhead/winged helix transcription factor, Foxp3, and were able to suppress the proliferation of CD4(+)CD25(-) cells. Importantly, a high frequency of Foxp3(+) cells accumulated at the site of infection and in dLNs. We next investigated the outcome of a reinfection with L. braziliensis in terms of Treg distribution and disease reactivation. Interestingly, a secondary inoculation with L. braziliensis did not preclude an efficient recall response to L. braziliensis at a distal site, despite the presence of Tregs. Within dLNs, reinfection did not promote parasite dissemination or a differential recruitment of either CD4(+)CD25(+)Foxp3(+) or CD4(+)IL-10(+) T cells. On the contrary, parasites were mainly detected in the LN draining the primary infection site where a high frequency of CD4(+)IFN-γ(+) T cells was also present. Collectively these data show that during experimental infection, Tregs are present in healed mice but this population does not compromise an effective immune response upon reinfection with L. braziliensis.
Copyright © 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22705204     DOI: 10.1016/j.ijpara.2012.05.006

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  12 in total

1.  The immunotherapeutic role of regulatory T cells in Leishmania (Viannia) panamensis infection.

Authors:  Allison Ehrlich; Tiago Moreno Castilho; Karen Goldsmith-Pestana; Wook-Jin Chae; Alfred L M Bothwell; Tim Sparwasser; Diane McMahon-Pratt
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

2.  Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Leishmania braziliensis Infection.

Authors:  Jéssica Rebouças-Silva; Maraine Catarina Tadini; Danielle Devequi-Nunes; Ana Luíza Mansur; Paulo S Silveira-Mattos; Camila I de Oliveira; Fábio R Formiga; Andresa A Berretta; Franciane Marquele-Oliveira; Valéria M Borges
Journal:  Int J Nanomedicine       Date:  2020-11-05

3.  The immunobiology of Leishmania braziliensis infection.

Authors:  Camila I de Oliveira; Claudia I Brodskyn
Journal:  Front Immunol       Date:  2012-06-08       Impact factor: 7.561

4.  Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.

Authors:  Diego M Santos; Antonio L O A Petersen; Fabiana S Celes; Valeria M Borges; Patricia S T Veras; Camila I de Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

5.  Immunity to Lutzomyia whitmani Saliva Protects against Experimental Leishmania braziliensis Infection.

Authors:  Regis Gomes; Katrine Cavalcanti; Clarissa Teixeira; Augusto M Carvalho; Paulo S Mattos; Juqueline R Cristal; Aline C Muniz; José Carlos Miranda; Camila I de Oliveira; Aldina Barral
Journal:  PLoS Negl Trop Dis       Date:  2016-11-03

6.  DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis.

Authors:  Fabiana S Celes; Eliane Trovatti; Ricardo Khouri; Johan Van Weyenbergh; Sidney J L Ribeiro; Valeria M Borges; Hernane S Barud; Camila I de Oliveira
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

7.  Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Marcia W Carneiro; Diego M Santos; Kiyoshi F Fukutani; Jorge Clarencio; Jose Carlos Miranda; Claudia Brodskyn; Aldina Barral; Manoel Barral-Netto; Manuel Soto; Camila I de Oliveira
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

8.  Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis.

Authors:  Fernanda O Novais; Lucas P Carvalho; Joel W Graff; Daniel P Beiting; Gordon Ruthel; David S Roos; Michael R Betts; Michael H Goldschmidt; Mary E Wilson; Camila I de Oliveira; Phillip Scott
Journal:  PLoS Pathog       Date:  2013-07-18       Impact factor: 6.823

9.  Differential Recruitment of Dendritic Cells Subsets to Lymph Nodes Correlates with a Protective or Permissive T-Cell Response during Leishmania (Viannia) Braziliensis or Leishmania (Leishmania) Amazonensis Infection.

Authors:  A K Carvalho; K Carvalho; L F D Passero; M G T Sousa; V L R da Matta; C M C Gomes; C E P Corbett; G E Kallas; F T Silveira; M D Laurenti
Journal:  Mediators Inflamm       Date:  2016-03-17       Impact factor: 4.711

10.  Malaria-Cutaneous Leishmaniasis Co-infection: Influence on Disease Outcomes and Immune Response.

Authors:  Raquel A Pinna; Danielle Silva-Dos-Santos; Daiana S Perce-da-Silva; Joseli Oliveira-Ferreira; Dea M S Villa-Verde; Paula M De Luca; Dalma M Banic
Journal:  Front Microbiol       Date:  2016-06-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.